Compare HUIZ & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | TPST |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 13.7M |
| IPO Year | 2019 | 2012 |
| Metric | HUIZ | TPST |
|---|---|---|
| Price | $2.10 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.4K | ★ 182.0K |
| Earning Date | 08-20-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | $6.27 | N/A |
| Revenue Next Year | $11.13 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.04 | $0.29 |
| 52 Week High | $3.83 | $4.22 |
| Indicator | HUIZ | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 49.77 | 20.25 |
| Support Level | $1.52 | N/A |
| Resistance Level | $2.16 | $0.56 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 27.66 | 4.46 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners. Geographically, the company is concentrated in PRC Mainland, Hong Kong and others segments.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.